An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Coherus BioSciences, Inc. will release its third quarter 2023 financial results on November 6, 2023, after market close. The management team will host a conference call and webcast to discuss the results and provide a business update. The conference call will take place on November 6, 2023, at 5:00 p.m. Eastern Time. Dial-in information and a personal PIN can be obtained by pre-registering through the provided link. The press release and related materials will be available on the company's website prior to the call, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, will be available on November 6, 2023.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Conference Call Information
When: Monday, November 6, 2023, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI0eececfba52f4f83a7438c9f002fabc4
A press release containing the third quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call. Please also review our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which will be available at https://investors.coherus.com and available via EDGAR on the SEC’s website at www.sec.gov on November 6, 2023 for more information about our third quarter financial results.
A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.
When will Coherus BioSciences release its third quarter 2023 financial results?
Coherus BioSciences will release its third quarter 2023 financial results on November 6, 2023, after market close.
When will the conference call and webcast to discuss the financial results take place?
The conference call and webcast to discuss the financial results will take place on November 6, 2023, starting at 5:00 p.m. Eastern Time.
How can I access the conference call?
To access the conference call, please pre-register through the provided link to receive dial-in information and a personal PIN.
Where can I find the press release and related materials?
The press release and related materials will be available on Coherus BioSciences' website prior to the start of the conference call.
Where can I find the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023?
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, will be available on Coherus BioSciences' website and via EDGAR on the SEC's website on November 6, 2023.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
